Streetbeat News

FENC

Fennec Pharmaceuticals Inc.

https://www.fennecpharma.com

Industry

Biotechnology

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Open

4.69

Mkt cap

119M

Volume

272K

High

4.69

P/E Ratio

62.29

52-wk high

11.92

Low

4.21

Div yield

N/A

52-wk low

4.09

HC Wainwright & Co. has maintained a Buy rating on Fennec Pharmaceuticals but lowered the price target from $15 to $13.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2024 | 1:09 pm

Craig-Hallum analyst Chase Knickerbocker maintains a Buy rating on Fennec Pharmaceuticals (NASDAQ:FENC) but lowers the price target from $17 to $15.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 12:46 pm

Fennec Pharmaceuticals announced that its cash and cash equivalents of $43.1 million as of June 30, 2024, will be sufficient to fund its planned operations for at least the next twelve months.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 10:08 am

Fennec Pharmaceuticals reported a Q2 2024 GAAP EPS of $(0.20), missing the estimate of $(0.03). Sales were $7.262 million, falling short of the $11.049 million estimate.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 10:06 am

Fennec Pharmaceuticals has appointed Jeff Hackman as its new CEO and a member of the board, effective on or about August 16, 2024.

Portfolio Pulse from Benzinga Newsdesk

August 05, 2024 | 10:27 am

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) announced the departure of its Chief Operating Officer, Adrian Haigh, effective June 30, 2024. Haigh joined the leadership team in August 2023 after serving as an independent director for nine years.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 10:08 am

Craig-Hallum analyst Chase Knickerbocker maintains a Buy rating on Fennec Pharmaceuticals (NASDAQ:FENC) but lowers the price target from $20 to $17.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 5:53 pm

HC Wainwright & Co. has maintained its Buy rating on Fennec Pharmaceuticals (NASDAQ:FENC) but lowered the price target from $18 to $15.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 11:10 am

Alibaba Group Holding Limited (NYSE:BABA) shares fell by around 7% following mixed Q1 financial results. Other stocks experienced significant movements, with notable gainers including Cheetah Net Supply Chain Service Inc. (NASDAQ:CTNT) and losers like Scorpius Holdings, Inc. (NASDAQ:SCPX).

Portfolio Pulse from Avi Kapoor

May 14, 2024 | 5:30 pm

Fennec Pharmaceuticals' shares are trading lower following the announcement of their Q1 financial results.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 5:20 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.